Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

Cowen IO Next SummitNovember 11, 202210:40 a.m. ET – fireside chat

Stifel Healthcare ConferenceNovember 15, 20228:35 a.m. ET – fireside chat

Evercore ISI HealthCONx ConferenceNovember 29, 202211:20 a.m. ET – fireside chat

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

Source: Nkarta, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• End of Day Message
• Trump’s Crypto News Triggers Market – Apeing Hits 12K+ Whitelist Members as XRP and SOL Stay in Focus as the Best Cryptos to Buy Today
• Hyundai U.S. EV Owners to Receive Automatic 10% Discount at All IONNA Fast‑Charging Stations via App and Plug & Charge